Comprehensive Stroke Center, Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala 35294-3280, USA.
Stroke. 2010 Feb;41(2):280-7. doi: 10.1161/STROKEAHA.109.563304. Epub 2009 Dec 31.
Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA).
Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD+/-microspheres (microS), tPA+TCCD+/-microS, and tPA+low-frequency ultrasound.
A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%-11.2%); tPA+TCCD, 11.1% (95% CI, 0%-28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%- 61.4%); and tPA alone, 2.9% (95% CI, 0%-8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%- 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%-24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD+/-microS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70-5.25; P=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44-3.60; P=0.67).
The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.
超声增强溶栓是一种很有前途的新方法,可以促进急性缺血性脑卒中的再灌注治疗。到目前为止,已经使用了 3 种不同的超声技术来增加组织型纤溶酶原激活物(tPA)的溶栓活性,包括经颅多普勒(TCD)、经颅彩色双功超声(TCCD)和低频超声。我们进行了一项荟萃分析,以评估超声增强溶栓与目前的标准治疗(静脉内 tPA)相比的安全性和有效性。
通过 Medline、Embase 和 Cochrane 数据库检索,我们确定并提取了所有关于急性脑缺血超声增强溶栓的研究。如果需要通过同行评议出版物以外的数据,我们会联系主要研究人员。比较 tPA、tPA+TCD+/-微球(微球)、tPA+TCCD+/-微球和 tPA+低频超声的症状性颅内出血(sICH)和再通率。
共纳入 6 项随机(n=224)和 3 项非随机(n=192)研究。随机研究中症状性颅内出血的发生率如下:tPA+TCD,3.8%(95%CI,0%-11.2%);tPA+TCCD,11.1%(95%CI,0%-28.9%);tPA+低频超声,35.7%(95%CI,16.2%-61.4%);tPA 单独使用,2.9%(95%CI,0%-8.4%)。接受 TCD 联合 tPA 治疗的患者完全再通率更高,为 37.2%(95%CI,26.5%-47.9%),而单独使用 tPA 的患者为 17.2%(95%CI,9.5%-24.9%)。在 8 项高频(TCD/TCCD)超声增强溶栓试验中,与单独使用 tPA 相比,tPA+TCD/TCCD+/-微球更有可能实现完全再通(汇总 OR,2.99;95%CI,1.70-5.25;P=0.0001)。高频超声增强溶栓治疗与症状性颅内出血风险增加无关(汇总 OR,1.26;95%CI,0.44-3.60;P=0.67)。
应考虑高频超声增强溶栓的现有安全性和疗效信号,在未来的随机对照试验设计中。